Organization
Hospital del Mar, Barcelona, Spain
18 abstracts
Abstract
Characterization of the immune microenvironment in matched primary and metastatic breast cancer lesions from the AURORA study: BIG 14-01.Org: Department of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, Netherlands, Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (HUB), Institut Jules Bordet, Academic Trials Promoting Team (ATPT), Brussels, Belgium, Fundación Instituto Valenciano de Oncología (FIVO), GEICAM Spanish Breast Cancer Group, Valencia, Spain, Breast Cancer Translational Research Laboratory J.-C. Heuson, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (HUB), Université Libre de Bruxelles (ULB), Brussels, Belgium, Department of Mathematics, Università degli Studi di Genova, San Martino, Italy,
Abstract
Use of liquid biomarker thymidine kinase activity (TKa) to predict outcome and progression in patients with metastatic breast cancer (MBC) in the GEICAM/2014-12 FLIPPER trial.Org: Hospital del Mar, Barcelona, Spain, CIBERONC-ISCIII, Biovica International AB, Hospital Clínico Universitario de Valencia, INCLIVA-Biomedical Research Institute,
Abstract
Ki67 as a prognostic factor in male breast cancer (male BC): Results from a large GEICAM Spanish cohort of male BC.Org: Gipuzkoa Cancer Unit- OSID/Onkologikoa-Osakidetza, GEICAM Spanish Breast Cancer Group, Hospital Universitario de Basurto, Hospital Clínico Universitario de Valencia, Institut Català d’Oncologia Hospitalet- Hospital Moises Broggi,
Abstract
Development of a multiparametric prognostic score based on PAM50, in patients with HR+/HER2- advanced breast cancer (aBC) treated with endocrine therapy (ET) plus cyclin dependent kinase 4 and 6 inhibitors (CDKi), within the CDK-PREDICT (SOLTI-1801) study and HCB cohort.Org: SOLTI Cancer Research Group, August Pi i Sunyer Biomedical Research Institute, Hospital Clínic de Barcelona, IDIBAPS, Biomedical Research Institute INCLIVA, Hospital Universitario 12 de Octubre Research Institute,
Abstract
Ipatasertib (IPA) combined with non-taxane chemotherapy (CT) for patients (pts) with previously treated advanced triple-negative breast cancer (aTNBC): The PATHFINDER phase IIa trial.Org: Medica Scientia Innovation Research (MEDSIR) - Oncoclínicas&Co, International Breast Cancer Center (IBCC), Pangaea Oncology, Quiron Group, Hospital Universitario Ramón y Cajal,
Abstract
Efficacy analysis of CDK4/6 inhibitors (CDKi) + endocrine therapy (ET) treatment in hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer (aBC): Biomarker analysis including chemoendocrine score (CES) by CDKi type in SOLTI-1801_CDK-PREDICT study.Org: Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, Hospital 12 de Octubre, Hospital Clínic de Barcelona, IDIBAPS, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), SOLTI Breast Cancer Cooperative Group,
Abstract
New ESMO scale for clinical actionability of molecular targets (ESCAT) for gliomas based on a multicentric real world data cohort using next-generation sequencing (NGS).Org: Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain, Hospital Universitario 12 de Octubre, Oncology Data Science (ODysSey) Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d´Hebron Institute of Oncology (VHIO), Institut Catala d'Oncologia Badalona,
Abstract
MAHOGANY: A phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab in patients with relapsed or refractory follicular or marginal zone lymphoma.Org: MD Anderson Cancer Center, Peking University Cancer Hospital and Institute (Beijing Cancer Hospital), Beijing, China, University of British Columbia, Institut Curie, Saint Cloud, France, University of Bologna,
Abstract
Analysis of tumor- and circulating-free DNA methylation to identify clinically relevant small cell lung cancer subtypes.Org: University of Texas MD Anderson Cancer Center, Department of Thoracic Head and Neck Medical Oncology, Epigenet & Mol Carcinogenesis, MD Anderson Cancer Center, Hospital del Mar, Barcelona, Spain,
Abstract
Development and independent validation of a predictive gene expression signature based on RB1, PTEN, and TP53 in patients with metastatic hormone-sensitive metastatic prostate cancer (mHSPC).Org: Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain, Translational Genomics and Targeted Therapeutics in Solid Tumors Lab, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, Hospital Clínic de Barcelona, Barcelona, Spain, Hospital Clínic Barcelona, Barcelona, Spain, Hospital Clinic de Barcelona, Barcelona, Spain,
Abstract
A GENOME-WIDE ASSOCIATION STUDY IDENTIFIES A NEW LOCUS ASOCIATED WITH THE RESPONSE TO ANTI-TNF THERAPY IN RHEUMATOID ARTHRITIS Org: Hospital Universitario Guadalajara, Guadalajara, Hospital Regional Universitario Carlos Haya, Málaga, Hospital Juan Canalejo, A Coruña, Hospital Universitario La Princesa, Madrid, Hospital Clínic de Barcelona, IDIBAPS,
Abstract
ADVANCEMENTS IN DIAGNOSING STIFFNESS AND VASCULARIZATION OF SYNOVITIS IN HANDS AND WRISTS USING SHEAR WAVE ELASTOGRAPHY AND COLOR-DOPPLER ULTRASOUND IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUSOrg: Hospital del Mar, Barcelona, Spain, Hospital Clinico Universitario de Valencia; INCLIVA; GEICAM Spanish Breast Cancer Group, Hospital del Mar Research Institute,
Abstract
ADVANCED GLYCATION END PRODUCTS IN SYSTEMIC SCLEROSISOrg: IDIBELLL, IMIM (Hospital del Mar Medical Research Institute), Inflammation and Cartilage Cellular Research Group, Barcelona, Spain, Hospital del Mar, Barcelona, Spain, Hospital Universitario Vall d’Hebron, VHIR,
Abstract
AN EXPERT CONSENSUS ON THE APPROPRIATE USE OF ORAL SYSADOAS FOR THE TREATMENT OF THE OSTEOARTHRITIC PATIENT IN PRIMARY HEALTH CARE: A DELPHI STUDYOrg: Hospital del Mar, Barcelona, Spain, Centro Salud Sagrado Corazón, Lugo, Spain, Hospital Clínic, Barcelona, Spain, Centro De Salud Y Atención Primaria Limonar, Málaga, Spain, Institut Poal de Reumatologia, Barcelona, Spain,
Abstract
ASSESSMENT OF NAILFOLD CAPILLAROSCOPY BY DIGITAL EPILUMINESCENCE (DERMOSCOPY) IN PATIENTS WITH RAYNAUD PHENOMENONOrg: Rheumatology, Society of Patients with Rheumatism, Cracow, Poland, Dermatology, UKM, Muenster, Germany, Hospital del Mar, Barcelona, Spain, Barcelona Clinic Liver Cancer, Spain,
Abstract
ABDOMINAL RADIOGRAPHS UNDERSTIMATE THE PREVALENCE OF PAGET'S DISEASE OF BONE IN A FIFHT OF PATIENTS Org: Sociedad Española De Reumatologia, Madrid, H. Clinic i Provincial, Hospital del Mar, Barcelona, Spain, H. German Trias i Pujol, Barcelona, Spain,
Abstract
A COMPARATIVE STUDY ON CLINICAL AND SEROLOGICAL CHARACTERISTICS BETWEEN PATIENTS WITH RHUPUS AND PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUSOrg: Hospital Clinic Barcelona, Hospital de Bellvitge, Hospital del Mar, Barcelona, Spain, Hospital General de Granollers, Hospital Comarcal de l’Alt Penedès,
Abstract
ASSOCIATION BETWEEN DISEASE ACTIVITY AND DAMAGE IN IDIOPATHIC INFLAMMATORY MYOPATHIES. DIFFERENCES BETWEEN INCIDENT AND PREVALENT CASESOrg: Hospital Universitario Infanta Sofía, Universidad Europea de Madrid, Unidad de Investigación, Sociedad Española de Reumatología, Madrid, Spain, Hospital del Mar, Barcelona, Spain,